Annual report pursuant to Section 13 and 15(d)

Business combinations - Proforma Information (Details)

v3.24.0.1
Business combinations - Proforma Information (Details) - USD ($)
$ in Thousands
5 Months Ended 12 Months Ended
Jun. 01, 2023
May 31, 2023
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Merger with TCR2 Therapeutics Inc.          
Acquisition-related costs incurred by TCR2     $ 7,300    
Gain on bargain purchase     22,049    
Share-based compensation expense     11,773 $ 18,240 $ 20,629
TCR2 Therapeutics          
Merger with TCR2 Therapeutics Inc.          
Share-based compensation expense   $ 1,000   11,400  
TCR2 Therapeutics          
Merger with TCR2 Therapeutics Inc.          
Revenue     60,281 27,148  
Net loss     (177,312) $ (301,879)  
Acquisition-related costs incurred by TCR2     9,000    
Gain on bargain purchase $ 22,049   22,000    
Acquisition-related costs     $ 7,346